American Regent v. Cipla: Multrys® Trace Elements Patent Dispute Consolidated in NJ
American Regent, Inc. asserted five patents protecting its Multrys® trace elements injection 4* USP product against generic challenger Cipla Limited in the District of New Jersey. The case was closed after just 43 days when the court consolidated it with a related earlier action — Civil Action No. 2:24-cv-8435 — concentrating all proceedings in one docket.
Multrys® patent fight folded into broader Cipla infringement action
On October 9, 2025, American Regent, Inc. filed Civil Action No. 2:25-cv-16422 in the District of New Jersey against Cipla Limited, asserting infringement of five US patents — US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2 — all relating to its Multrys® trace elements injection 4* USP product supplied in 1 mL single-dose vials. The filing followed an earlier parallel action (No. 2:24-cv-8435) brought against both Cipla USA, Inc. and Cipla Limited on substantially overlapping subject matter.
After only 43 days, on November 21, 2025, the case was terminated not on the merits but through consolidation. All parties, through counsel, jointly requested — and the court agreed — that Civil Action Nos. 2:24-cv-8435 and 2:25-16422 be merged, with all papers going forward maintained under the earlier 2024 docket. This procedural closure means no substantive ruling, claim construction, or infringement finding was issued in this action.
The speed of consolidation — less than six weeks from filing — suggests the parties and court recognised the substantial overlap between the two actions from the outset, consistent with standard ANDA litigation practice where multiple patent certifications generate successive lawsuits. The consolidated 2024 action now carries the full weight of American Regent’s five-patent campaign against Cipla, and its outcome will determine the commercial stakes for Multrys® generic entry. The public record of the 2025 case itself is silent on claim-specific disputes, discovery, or licensing discussions.
Filing to Case Consolidated in 43 days
43 days — resolved by consolidation before substantive litigation commenced
Case consolidated: what the merger into 2:24-cv-8435 means for both parties
Consolidation ends this docket — litigation continues elsewhere
Court consolidation under Federal Rule of Civil Procedure 42(a) merges actions sharing common questions of law or fact. Here, both cases involve the same parties and the same Multrys® patents against the same defendant. The 2025 case is administratively closed — not dismissed — meaning no rights are extinguished. All claims, defences, and discovery are absorbed into Civil Action No. 2:24-cv-8435.
No merits ruling issuedAmerican Regent consolidates its full patent arsenal in one action
Consolidation benefits American Regent by allowing all five asserted patents to be litigated in a single, coordinated proceeding. This avoids inconsistent rulings across parallel dockets and reduces the risk of piecemeal outcomes. With the 30-month stay mechanism typical in Hatch-Waxman litigation, consolidation also preserves American Regent’s ability to maintain market exclusivity for Multrys® while the merged case proceeds.
Five patents active in merged caseCipla faces consolidated five-patent challenge on single docket
For Cipla Limited, consolidation concentrates all patent exposure into one venue and one judge, which can streamline invalidity and non-infringement defences but also means facing a broader patent portfolio in a single proceeding. Cipla must now coordinate its defence across all five asserted patents simultaneously under the 2024 case schedule, potentially accelerating or intensifying pre-trial obligations.
Defence consolidated under 2024 docketMultrys® market entry timeline now turns on 2024 case outcome
Trace elements injection products like Multrys® serve critical parenteral nutrition markets. With five patents in play and litigation now consolidated, the earliest possible generic entry date for Cipla’s product is tied entirely to the resolution of the merged action. Healthcare procurement teams and competing manufacturers should monitor Civil Action No. 2:24-cv-8435 as the single controlling proceeding for Multrys® patent exclusivity.
Watch docket 2:24-cv-8435Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer and NDA holder — asserting five patents on Multrys® trace elements injectionSearch in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Indian generic pharmaceutical company; ANDA filer targeting Multrys® trace elements injection formulationSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a consensual procedural resolution — all parties agreed to merge the 2025 action into the earlier 2024 case. The order makes no findings on infringement, validity, or claim scope. Legally, the 2025 case is closed but not dismissed; all claims survive in the consolidated docket. The phrasing ‘good cause exists to consolidate’ is standard language indicating judicial economy rather than any substantive determination about the merits of either party’s position.
US12150956B2 — Trace Elements Injection 4* USP Formulations (Multrys®)
The five asserted patents — US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2 — form a continuation-based patent family protecting American Regent’s Multrys® trace elements injection 4* USP product, supplied in 1 mL single-dose vials. The application numbers span filings from approximately 2022 to 2024, consistent with a strategy of pursuing overlapping claim sets as the product gained regulatory approval. Trace elements injections supply essential micronutrients — including zinc, copper, manganese, and selenium — intravenously to patients who cannot absorb nutrients enterally.
The breadth of a five-patent continuation family in this space creates significant defensive barriers for generic ANDA filers. Even if one patent is invalidated or designed around, the remaining family members may independently block market entry. For competitors, this portfolio structure — with patents issuing at different times from related applications — is consistent with a strategy to maintain Hatch-Waxman litigation leverage across multiple patent certification cycles. The clinical criticality of parenteral trace elements in hospital and home infusion settings amplifies the commercial stakes of any patent outcome.
Should you run an FTO against US12150956B2 and the Multrys® patent family?
Any company developing, manufacturing, or commercialising trace elements injection products for parenteral nutrition — including generic ANDA filers, 505(b)(2) applicants, or innovators formulating multi-trace-element IV products — should treat this five-patent family as a priority FTO target. The continuation structure means claim scope may vary meaningfully across family members, and one or more patents may capture process, formulation, or concentration parameters that a seemingly different product still infringes.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US12150956B2 and its four related patents, identify prosecution history estoppel, and surface prior art that may support invalidity arguments. For R&D teams designing around this portfolio, Eureka can identify the specific claim limitations most likely to create freedom — or risk — before you commit to a formulation strategy or regulatory filing.
Run a freedom-to-operate analysis on US12150956B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Trace Elements & Injectable Pharma Patent Cases
Explore related pharmaceutical patent infringement cases in the NJ District Court involving parenteral nutrition injectables, ANDA challenges, and multi-patent continuation families.
What this case signals for the parenteral nutrition IP landscape
A five-patent enforcement campaign consolidated into one NJ docket sets up a high-stakes Hatch-Waxman battle over a critical injectable product.
Multi-patent ANDA suits are increasingly filed in rapid succession
American Regent’s sequential filings in 2024 and 2025 reflect a common Hatch-Waxman strategy: filing new actions as additional patents issue or new ANDA certifications arrive. Consolidation is the predictable judicial response. IP teams tracking NDA-holders’ patent portfolios should anticipate multiple filings and plan for consolidated proceedings.
Consolidation does not reduce patent risk — it concentrates it
For generic entrants and FTO analysts, the closure of the 2025 case should not be read as a win or de-escalation. All five patents remain actively litigated. Companies with products that compete with or incorporate trace elements injection technology should monitor the 2024 action for claim construction rulings that could affect the sector broadly.
American v Cipla — key questions answered
The case was closed after 43 days via a consolidation order that merged it into the earlier related action, Civil Action No. 2:24-cv-8435. All parties consented to consolidation, and all papers are now maintained in the 2024 docket. No merits ruling, claim construction, or infringement finding was issued in the 2025 case.
American Regent asserted five US patents: US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2. All relate to Multrys® trace elements injection 4* USP supplied in 1 mL single-dose vials. The patents form a continuation family with application numbers filed between approximately 2022 and 2024.
Consolidation means the 2025 case is administratively closed but not dismissed. All claims, defences, and patent assertions are absorbed into Civil Action No. 2:24-cv-8435. The litigation continues under that docket, and any ruling on infringement or validity will be issued there. Neither party’s substantive rights were affected by the consolidation.
The public record does not confirm the status of a 30-month stay or any preliminary injunction in the consolidated action. However, with five patents asserted and litigation active in the 2024 case, any generic launch by Cipla before resolution would constitute an at-risk launch. The consolidated proceeding in docket 2:24-cv-8435 will determine the patent exclusivity timeline.
The public record does not specify the precise trigger for the 2025 filing. In Hatch-Waxman litigation, subsequent actions are typically filed when additional patents issue and receive Paragraph IV certifications after the original complaint, or when amended ANDA filings create new certification obligations. The rapid consolidation of both cases suggests the overlap in subject matter was apparent from the outset.
PatSnap Eureka searches patents and litigation data to answer instantly.